388 related articles for article (PubMed ID: 27913543)
21. Economical comparison of APCC vs. rFVIIa for mild-to-moderate bleeding episodes in haemophilia patients with inhibitors.
Hay JW; Zhou ZY
Haemophilia; 2011 Sep; 17(5):e969-74. PubMed ID: 21649802
[TBL] [Abstract][Full Text] [Related]
22. Economic analysis of recombinant activated factor VII versus plasma-derived activated prothrombin complex concentrate in mild to moderate bleeds: haemophilia registry data from the Czech Republic.
Salaj P; Penka M; Smejkal P; Geierova V; Ovesná P; Brabec P; Cetkovsky P; Kubes R; Mesterton J; Lindgren P
Thromb Res; 2012 May; 129(5):e233-7. PubMed ID: 22386136
[TBL] [Abstract][Full Text] [Related]
23. Cost-effectiveness of recombinant activated factor VII vs. plasma-derived activated prothrombin complex concentrate in the treatment of mild-to-moderate bleeding episodes in patients with severe haemophilia A and inhibitors in Spain.
Jimenez-Yuste V; Núñez R; Romero JA; Montoro B; Espinós B
Haemophilia; 2013 Nov; 19(6):841-6. PubMed ID: 23758100
[TBL] [Abstract][Full Text] [Related]
24. Thromboembolic Risks of Non-Factor Replacement Therapies in Hemophilia.
Tiede A
Hamostaseologie; 2017; 37(4):307-310. PubMed ID: 29582931
[No Abstract] [Full Text] [Related]
25. Health economics in haemophilia: a review from the clinician's perspective.
Escobar MA
Haemophilia; 2010 May; 16 Suppl 3():29-34. PubMed ID: 20586799
[TBL] [Abstract][Full Text] [Related]
26. Experiences in the prevention of arthropathy in haemophila patients with inhibitors.
Jimenez-Yuste V; Rodriguez-Merchan EC; Alvarez MT; Quintana M; Martin-Salces M; Hernandez-Navarro F
Haemophilia; 2008 Nov; 14 Suppl 6():28-35. PubMed ID: 19134031
[TBL] [Abstract][Full Text] [Related]
27. Treatment patterns and cost-of-illness of severe haemophilia in patients with inhibitors in Germany.
Auerswald G; von Depka Prondzinski M; Ehlken B; Kreuz W; Kurnik K; Lenk H; Scharrer I; Schramm W; Zimmermann R
Haemophilia; 2004 Sep; 10(5):499-508. PubMed ID: 15357777
[TBL] [Abstract][Full Text] [Related]
28. Recombinant factor VIIa versus aPCCs in haemophiliacs with inhibitors: treatment and cost considerations.
Teitel JM
Haemophilia; 1999 Sep; 5 Suppl 3():43-9. PubMed ID: 10597387
[No Abstract] [Full Text] [Related]
29. Cost of care of haemophilia with inhibitors.
Di Minno MN; Di Minno G; Di Capua M; Cerbone AM; Coppola A
Haemophilia; 2010 Jan; 16(1):e190-201. PubMed ID: 19845772
[TBL] [Abstract][Full Text] [Related]
30. What does the 'Cochrane database of systematic reviews' tell us about hemophilia?
Rodriguez-Merchan EC
Expert Rev Hematol; 2019 Nov; 12(11):919-922. PubMed ID: 31610130
[No Abstract] [Full Text] [Related]
31. Dose optimization of recombinant factor VIIa for control of mild to moderate bleeds in inhibitor patients: Improved efficacy with higher dosing.
Abshire TC
Semin Hematol; 2004 Jan; 41(1 Suppl 1):3-7. PubMed ID: 14872413
[TBL] [Abstract][Full Text] [Related]
32. How we use recombinant activated Factor VII in patients with haemophilia A or B complicated by inhibitors. Working group of hematology experts from Australia and New Zealand, Melbourne, April 2011.
Brown SA; Barnes C; Curtin J; Dunkley S; Ockelford P; Phillips J; Rowell J; Smith M; Tran H;
Intern Med J; 2012 Nov; 42(11):1243-50. PubMed ID: 23157518
[TBL] [Abstract][Full Text] [Related]
33. When should prophylaxis therapy in inhibitor patients be considered?
Young G; Auerswald G; Jimenez-Yuste V; Konkle BA; Lambert T; Morfini M; Santagostino E; Blanchette V
Haemophilia; 2011 Sep; 17(5):e849-57. PubMed ID: 21418444
[TBL] [Abstract][Full Text] [Related]
34. Current opinion on inhibitor treatment options.
Mathew P
Semin Hematol; 2006 Apr; 43(2 Suppl 4):S8-13. PubMed ID: 16690374
[TBL] [Abstract][Full Text] [Related]
35. Successful immune tolerance induction with low-dose coagulation factor VIII in a patient with hemophilia A from a developing country.
Ay Y; Ersin T; Yesim O; Hilkay KT; Dilek I; Gulcihan O; Ahmet K
Blood Coagul Fibrinolysis; 2016 Sep; 27(6):729-31. PubMed ID: 26484639
[TBL] [Abstract][Full Text] [Related]
36. Prevention of bleeds in hemophilia patients with inhibitors: emerging data and clinical direction.
Leissinger CA
Am J Hematol; 2004 Oct; 77(2):187-93. PubMed ID: 15389908
[TBL] [Abstract][Full Text] [Related]
37. Elective orthopaedic surgery for haemophilia patients with inhibitors: single centre experience of 40 procedures and review of the literature.
Caviglia H; Candela M; Galatro G; Neme D; Moretti N; Bianco RP
Haemophilia; 2011 Nov; 17(6):910-9. PubMed ID: 21342367
[TBL] [Abstract][Full Text] [Related]
38. Prevention of bleeding in hemophilia patients with high-titer inhibitors.
Leissinger CA; Konkle BA; Antunes SV
Expert Rev Hematol; 2015 Jun; 8(3):375-82. PubMed ID: 25937074
[TBL] [Abstract][Full Text] [Related]
39. Management of difficult-to-treat inhibitor patients.
Giangrande PL; Escobar MA
Haemophilia; 2010 May; 16 Suppl 3():52-7. PubMed ID: 20586803
[TBL] [Abstract][Full Text] [Related]
40. Prophylaxis in congenital hemophilia with inhibitors: the role of recombinant activated factor VII.
Franchini M; Manzato F; Salvagno GL; Montagnana M; Zaffanello M; Lippi G
Semin Thromb Hemost; 2009 Nov; 35(8):814-9. PubMed ID: 20169518
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
